$30M Private Placement Led by Nantahala Could Bring Up to $90M to Femasys
FEMY is trading near its 52-week low of $2.6 (3.1% above the low) on elevated volume (3.8× avg).
Summary
Femasys secures a $30M private placement at $3.20 per share, a premium to the $2.68 market price, signaling strong institutional demand. The deal includes warrants that could bring total proceeds to $90M if fully exercised, with milestone warrants tied to hitting $1.5M in quarterly U.S. revenue and a 130% VWAP trigger. This financing follows the June reverse split and Nasdaq compliance, providing runway to advance the FemBloc clinical program and commercialize the fertility portfolio. The participation of Nantahala Capital and Rosalind Advisors adds credibility, and management's own investment underscores internal conviction. The capital infusion addresses the going concern risk flagged in the last 10-Q, though dilution from potential warrant exercise is significant.
At the time of this announcement, FEMY was trading at $2.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.1M. The 52-week trading range was $2.60 to $22.20. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.